This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A phase 2a, double-blind, placebo-controlled study...
Clinical trial

A phase 2a, double-blind, placebo-controlled study of TCN-032 (human monoclonal antibody directed against the M2 protein of Influenza A Virus) in subjects challenged with H3N2 Influenza A Virus

Read time: 1 mins
Last updated:25th Apr 2012
The primary objective is to evaluate the effect of TCN-032 compared to placebo in the development of influenza symptoms Grade 2 or higher, or pyrexia, from Day 1 to Day 7, after viral challenge.
Category Value
Study start date 2012-04-25

View full details